---
title: "Antengene announced the latest Phase I/II clinical data for ATG-022 in treating gastric cancer with an ORR of 42.9%"
description: "Antengene Corporation announced the latest Phase I/II clinical data for ATG-022 in the treatment of advanced or metastatic gastric cancer, with an ORR of 42.9%. This drug is an antibody-drug conjugate"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/225792440.md"
published_at: "2025-01-22T07:25:34.000Z"
---

# Antengene announced the latest Phase I/II clinical data for ATG-022 in treating gastric cancer with an ORR of 42.9%

> Antengene Corporation announced the latest Phase I/II clinical data for ATG-022 in the treatment of advanced or metastatic gastric cancer, with an ORR of 42.9%. This drug is an antibody-drug conjugate targeting the CLDN18.2 protein, demonstrating good clinical efficacy. ATG-022 has received orphan drug designation from the FDA for gastric cancer and pancreatic cancer

Antengene Corporation today announced that the latest data from the CLINCH study, which is evaluating ATG-022 for the treatment of advanced or metastatic gastric cancer patients in China and Australia, will be presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. ATG-022 is an antibody-drug conjugate targeting the tight junction protein CLDN18.2, which is a type of cell adhesion molecule. The U.S. Food and Drug Administration has granted ATG-022 two orphan drug designations for the treatment of gastric cancer and pancreatic cancer. Data from the ongoing CLINCH study indicate that ATG-022 has shown good clinical efficacy in gastric cancer patients with varying levels of CLDN18.2 expression. The efficacy demonstrated in gastric cancer populations with different CLDN18.2 expression levels suggests that ATG-022 has the potential to become a highly competitive drug

### Related Stocks

- [06996.HK - ANTENGENE-B](https://longbridge.com/en/quote/06996.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 金監總局約談攜程高德等六家出行平台 借貸業務存在問題 | 金融監管總局與市監局對攜程旅行、高德地圖、飛豬旅行、同程旅行、航旅縱橫和去哪兒旅行等六家出行平臺進行約談，指出其在借貸業務中存在問題。要求企業規範營銷行為，避免誤導性宣傳，清晰披露貸款信息，提示理性借貸，並改善客戶投訴處理，提升服務質量，保 | [Link](https://longbridge.com/en/news/275891504.md) |
| 經濟嚴峻成併購機遇 利華：正物色南美洲北非等地企業 | 利華控股主席司徒志仁表示，儘管經濟環境嚴峻，但這反而為收購服裝公司提供了機會，正在物色南美洲和北非的企業。去年因客户拖欠貨款導致收入下跌的影響已減退，預計今年可重拾增長。公司去年收入為 2 億美元，下降 10.2%，純利 1587 萬美元， | [Link](https://longbridge.com/en/news/275864454.md) |
| 奧運會冰壺賽 - 中國隊隊長徐認為農曆新年期間的勝利預示着未來的好運 | 中國的冰壺隊隊長徐曉明在米蘭 - 科爾蒂納冬奧會上取得兩場勝利後表達了樂觀的態度，這恰逢農曆新年。徐曉明強調，這些勝利在馬年具有重要意義，暗示它們為未來的比賽帶來了良好的預兆。作為一名有教練背景的選手，徐曉明希望能指導年輕球員度過奧運經歷。 | [Link](https://longbridge.com/en/news/276141927.md) |
| 達利歐萬字長文：舊秩序已死，世界重回 “叢林法則”，貿易戰和資本戰將成常態 | 達利歐宣告世界進入 “大週期” 第六階段：1945 年後的世界秩序已瓦解，強權即公理，大國衝突將回歸原始權力博弈，貿易戰、技術戰、資本戰將常態化並可能升級為軍事衝突。慕尼黑安全會議共識印證這一判斷：舊秩序已不復存在，歐洲安全架構失效。達利歐 | [Link](https://longbridge.com/en/news/276003775.md) |
| 永利澳門在 2025 年第四季度調整後的税前收益下降 | 永利澳門 2025 年第四季度調整後的税前收益下降 | [Link](https://longbridge.com/en/news/275832737.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.